Ipertrofia prostatica benigna e Mepartricina

Translated title of the contribution: Benign prostate hypertrophy and Mepartricin

A. F. De Rose, G. Carmignani

Research output: Contribution to journalArticle

Abstract

Estrogens can lead to benign prostatic hypertrophy (BPH) through two different ways: a) acting directly on stroma by specific receptors; b) increasing DHT prostatic receptors. Mepartricin performs an anti-estrogenic action at intestinal level only, increasing fecal excretion and reducing their serum and prostatic level. A European study evaluated 178 patients, 88 treated with Mepartricin and 98 with placebo. The group treated with Mepartricin showed from the first month a better urinary flow and a significant decrease of IPSS score.

Original languageItalian
Pages (from-to)51-53
Number of pages3
JournalRivista Italiana di Biologia e Medicina
Volume17
Issue number3-4
Publication statusPublished - 1997

Fingerprint

Mepartricin
Hypertrophy
Prostate
Prostatic Hyperplasia
Estrogens
Placebos
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

De Rose, A. F., & Carmignani, G. (1997). Ipertrofia prostatica benigna e Mepartricina. Rivista Italiana di Biologia e Medicina, 17(3-4), 51-53.

Ipertrofia prostatica benigna e Mepartricina. / De Rose, A. F.; Carmignani, G.

In: Rivista Italiana di Biologia e Medicina, Vol. 17, No. 3-4, 1997, p. 51-53.

Research output: Contribution to journalArticle

De Rose, AF & Carmignani, G 1997, 'Ipertrofia prostatica benigna e Mepartricina', Rivista Italiana di Biologia e Medicina, vol. 17, no. 3-4, pp. 51-53.
De Rose, A. F. ; Carmignani, G. / Ipertrofia prostatica benigna e Mepartricina. In: Rivista Italiana di Biologia e Medicina. 1997 ; Vol. 17, No. 3-4. pp. 51-53.
@article{ba3cea58260e41e1bba9df6fab926c1a,
title = "Ipertrofia prostatica benigna e Mepartricina",
abstract = "Estrogens can lead to benign prostatic hypertrophy (BPH) through two different ways: a) acting directly on stroma by specific receptors; b) increasing DHT prostatic receptors. Mepartricin performs an anti-estrogenic action at intestinal level only, increasing fecal excretion and reducing their serum and prostatic level. A European study evaluated 178 patients, 88 treated with Mepartricin and 98 with placebo. The group treated with Mepartricin showed from the first month a better urinary flow and a significant decrease of IPSS score.",
keywords = "Androgen, Benign prostatic hypertrophy, Estrogen, Mepartricin",
author = "{De Rose}, {A. F.} and G. Carmignani",
year = "1997",
language = "Italian",
volume = "17",
pages = "51--53",
journal = "Rivista Italiana di Biologia e Medicina",
issn = "0393-1137",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3-4",

}

TY - JOUR

T1 - Ipertrofia prostatica benigna e Mepartricina

AU - De Rose, A. F.

AU - Carmignani, G.

PY - 1997

Y1 - 1997

N2 - Estrogens can lead to benign prostatic hypertrophy (BPH) through two different ways: a) acting directly on stroma by specific receptors; b) increasing DHT prostatic receptors. Mepartricin performs an anti-estrogenic action at intestinal level only, increasing fecal excretion and reducing their serum and prostatic level. A European study evaluated 178 patients, 88 treated with Mepartricin and 98 with placebo. The group treated with Mepartricin showed from the first month a better urinary flow and a significant decrease of IPSS score.

AB - Estrogens can lead to benign prostatic hypertrophy (BPH) through two different ways: a) acting directly on stroma by specific receptors; b) increasing DHT prostatic receptors. Mepartricin performs an anti-estrogenic action at intestinal level only, increasing fecal excretion and reducing their serum and prostatic level. A European study evaluated 178 patients, 88 treated with Mepartricin and 98 with placebo. The group treated with Mepartricin showed from the first month a better urinary flow and a significant decrease of IPSS score.

KW - Androgen

KW - Benign prostatic hypertrophy

KW - Estrogen

KW - Mepartricin

UR - http://www.scopus.com/inward/record.url?scp=0031419766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031419766&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0031419766

VL - 17

SP - 51

EP - 53

JO - Rivista Italiana di Biologia e Medicina

JF - Rivista Italiana di Biologia e Medicina

SN - 0393-1137

IS - 3-4

ER -